• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

June 3, 2015

View Archived Issues

Astellas first taker for Anokion's immune tolerance technology in potential $760M deal

Anokion SA is spinning out a new start-up, Kanyos Bio Inc., to serve as the vehicle for a development alliance in autoimmune disease with Astellas Pharma Inc., which could be worth up to $760 million in R&D funding, option exercise payments and milestones. Read More

Luye calls off $1B Jialin buy; seeks other M&A deals

HONG KONG – In a move that sent its stock down more than 3 percent Tuesday, Hong Kong-listed Chinese pharmaceutical company Luye Pharma Group (HK:2186) terminated a billion-dollar acquisition deal. Read More

Cancer in the crosshairs: ASCO brings fresh ideas, data jubilee across types

CHICAGO – No one was surprised to see immune-based therapies taking much of the air time at this year's American Society of Clinical Oncology (ASCO) meeting, since they've dominated the key scientific powwow in cancer for several years, and a fountain of outcomes showed that targeted drugs, in combination regimens as well as single agents, still have plenty going for them. Read More

Less toxic antifungal derivatives remain resistance-resistant

For antimicrobials, toxicity and the ability to prevent resistance from evolving are widely considered two sides of the same coin. But researchers from the University of Illinois at Urbana-Champaign and The Whitehead Institute have shown that it is possible to separate those two aspects of drugs. Read More

Eddingpharm mining Europe's assets, signs JV with Spain's Faes

SHANGHAI – Eddingpharm Co. Ltd. has found its niche: in-licensing specialty products looking to fill a gap in China's medicinal arsenal. Read More

Extra ASCO Coverage, from Cortellis

BioWorld is pleased to share Cortellis conference reports from ASCO. The Thomson Reuters Cortellis team covers more than 200 key scientific and biopharma conferences per year, producing nearly 300 such reports. Read More

Other news to note

Lipocine Inc., of Salt Lake City, said the FDA granted orphan status to LPCN 1107, its oral hydroxyprogesterone caproate product candidate, a potential treatment for the prevention of preterm birth. Lipocine previously reported positive phase Ib top-line data with LPCN 1107 in pregnant women. Read More

Financings

Cytori Therapeutics Inc., of San Diego, said it entered a four-year, $17.7 million term loan with Oxford Finance LLC. The terms of the loan provide for an interest-only payment period of at least 12 months with the potential to be extended up to 18 months. Read More

Stock movers

Read More

ASCO 2015

TG Therapeutics Inc., of New York, reported clinical results from two ongoing studies of its oral, once-daily, PI3K delta inhibitor, TGR-1202, as a single agent and in combination with TG-1101 (ublituximab), the company's glycoengineered anti-CD20 monoclonal antibody. Read More

In the clinic

Aphios Corp., of Woburn, Mass., said enrollment has completed in a phase I/II trial of APH-0812 for HIV latency. APH-0812 consists of a PKC modulator such as bryostatin-1 and/or an HDAC inhibitor to reactivate latent HIV reservoirs so that HIV-1 can be eliminated from the body by antiviral therapy or immunotherapy and eradicated from the patient's body. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 7, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 7, 2025.
  • U.S. Capitol building, Washington D.C.

    House passes H.R. 1, restoring R&D tax cuts

    BioWorld MedTech
    The House of Representatives passed H.R. 1, also known as One Big Beautiful Bill, which will restore personal income tax cuts that expired in 2022. However, the...
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe